Medication info
Telmisartan/Rosuvastatin 40/10 mg

Telmisartan/Rosuvastatin 40/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Light blue oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201907247 · Approved 2019.10.15 · Insurance code 657806750

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, telmisartan Cmax was approximately 0.87-fold and AUC was approximately 1.00-fold; in the presence of telmisartan, rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when coadministered with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The effect of doses below 80 mg on reducing the risk of cardiovascular morbidity and mortality is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk and inhibition of atherosclerosis progression

  • Essential Hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who need to take both telmisartan and rosuvastatin simultaneously. Telmisartan helps reduce the risk of cardiovascular diseases along with the treatment of essential hypertension. It is particularly effective in reducing the risk of myocardial infarction, stroke, and death from cardiovascular diseases in high-risk patients aged 55 or older who cannot use ACE inhibitors. Rosuvastatin Calcium is used as an adjunct for patients with hypercholesterolemia and dyslipidemia when dietary and exercise measures are insufficient, lowering LDL cholesterol and delaying the progression of atherosclerosis. Additionally, it reduces the risk of stroke and myocardial infarction in high-risk cardiovascular disease patients. Therefore, this medication is used to treat high-risk cardiovascular patients with hypertension and dyslipidemia.

How to take

Adult dose

In a drug interaction study of the active ingredients in this medicine, telmisartan 80mg and rosuvastatin 20mg, in the presence of rosuvastatin, telmisartan Cmax was approximately 0.87-fold and AUC was approximately 1.00-fold; in the presence of telmisartan, rosuvastatin Cmax increased approximately 1.71-fold and AUC approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk resulting from the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when coadministered with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The effect of doses below 80 mg on reducing the risk of cardiovascular morbidity and mortality is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are allergic to this medication or its components, who are pregnant or may become pregnant, or who are breastfeeding should not take this medication. It is advisable not to use this medication in patients with severe liver dysfunction or problems with bile flow. Patients with muscle disorders or a family history of hereditary angioedema, as well as those with severe renal impairment, may be at risk when taking this medication. Patients on certain immunosuppressants or those with diabetes and severe renal impairment should not take this medication together. Since this medication contains lactose, patients with lactose intolerance or related genetic disorders should not take it. Elderly patients, patients with high potassium levels, and those with mild liver impairment should use this medication cautiously, and should have regular liver function tests and muscle-related tests. If symptoms like muscle pain or weakness occur, seek medical advice immediately, and medication may be discontinued if necessary. This medication has a blood pressure-lowering effect, so caution is advised as symptoms like hypotension, dizziness, and fainting may occur. Serious side effects such as liver dysfunction, angioedema, hyperkalemia, and renal impairment may occur, and any unusual symptoms should be reported to medical personnel immediately. This medication may interact with other medications, so inform your doctor or pharmacist of any other medications being taken. In cases of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, requiring immediate treatment. During treatment with this medication, be cautious when driving or operating machinery as drowsiness or dizziness may occur. Keep out of reach of children and do not transfer to another container for safety.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased diastolic blood pressure, hypotension, increased ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, increased urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver dysfunction, increased sweating, itching, rash, erythema, vascular edema, drug eruption, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle spasms, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated CK in the blood, decreased hemoglobin, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, headache, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, rash, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, hypoglycemia, vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from light and air, and keep it at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

Light blue oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.